ZLT-L-007 / Zelira Therapeutics - LARVOL DELTA

Zelira Therapeutics’ diabetic nerve pain drug outperforms Pfizer’s Lyrica (Small Caps) - P=NA | N=NA | "Perth-based Zelira Therapeutics...has confirmed its cannabinoid-based diabetic nerve pain drug ZLT-L-007 has outperformed Pfizer’s commercially-available medication Lyrica (Pregabalin) in a multi-arm, head-to-head, US-based clinical trial....Topline results demonstrated that ZLT-L-007 achieved a significant reduction in NRS (numerical rating scale) pain scores, indicating a decrease in symptom severity."

Clinical data • CNS Disorders • Diabetic Neuropathy • Neuralgia • Pain • Peripheral Neuropathic Pain